Thinking outside the (black) box: A new research agenda

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 6, 2006, Pages 387-389

  Seligman, Paul J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; KETOROLAC; METHOTREXATE; RITONAVIR;

DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL DECISION MAKING; NOTE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

DRUG LABELING; DRUG UTILIZATION; GUIDELINE ADHERENCE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745774356     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1205     Document Type: Note

References (1)

1. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369-386.